Get started
Author

Ignacio Casarini

Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial
2019 · Luis Paz-Ares, Mikhail Dvorkin, et al. · The Lancet · 2,281
Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial
2020 · Jonathan W Goldman, Mikhail Dvorkin, et al. · The Lancet Oncology · 688
Osimertinib after Chemoradiotherapy in Stage III EGFR -Mutated NSCLC
2024 · Shun Lu, Terufumi Kato, et al. · New England Journal of Medicine · 347
First-Line Lenvatinib Plus Pembrolizumab Versus Chemotherapy for Advanced Endometrial Cancer: A Randomized, Open-Label, Phase III Trial
2024 · Christian Marth, Richard G. Moore, et al. · Journal of Clinical Oncology · 68
Osimertinib Maintenance After Definitive Chemoradiation in Patients With Unresectable EGFR Mutation Positive Stage III Non–small-cell Lung Cancer: LAURA Trial in Progress
2021 · Shun Lu, Ignacio Casarini, et al. · Clinical Lung Cancer · 63
Subcutaneous versus intravenous pembrolizumab, in combination with chemotherapy, for treatment of metastatic non-small-cell lung cancer: the phase III 3475A-D77 trial
2025 · E. Felip, C.I. Rojas, et al. · Annals of Oncology · 40
PDF
Targeted treatment for unresectable EGFR mutation-positive stage III non-small cell lung cancer: Emerging evidence and future perspectives
2023 · Terufumi Kato, Ignacio Casarini, et al. · Lung Cancer · 19
Lenvatinib Plus Pembrolizumab, Pemetrexed, and a Platinum as First-Line Therapy for Metastatic Nonsquamous NSCLC: Phase 3 LEAP-006 Study
2025 · Roy S. Herbst, Byoung Chul Cho, et al. · Journal of Thoracic Oncology · 13
PDF
121P MK-7684A (vibostolimab [vibo] plus pembrolizumab [pembro] coformulation) with/without docetaxel in metastatic NSCLC after platinum-chemotherapy (chemo) and immunotherapy
2023 · N. Peled, J. Mazieres, et al. · Immuno-Oncology Technology · 13
Osimertinib (osi) after definitive chemoradiotherapy (CRT) in patients (pts) with unresectable stage (stg) III epidermal growth factor receptor-mutated (EGFRm) NSCLC: Primary results of the phase 3 LAURA study.
2024 · Suresh S. Ramalingam, Terufumi Kato, et al. · Journal of Clinical Oncology · 12
PDF
LBA4: Osimertinib (osi) after definitive chemoradiotherapy (CRT) in patients (pts) with unresectable (UR) stage III EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC): Updated overall survival (OS) analysis from the LAURA study
2025 · S.S. Ramalingam, M. Ozguroglu, et al. · Journal of Thoracic Oncology · 11
PDF
1463 Coformulated vibostolimab/pembrolizumab plus chemotherapy as first-line therapy vs atezolizumab plus chemotherapy for extensive-stage small-cell lung cancer (ES-SCLC): randomized, phase 3 KEYVIBE-008
2024 · Jacob Sands, Shun Lu, et al. · 5
64O Lenvatinib plus pembrolizumab, pemetrexed, and a platinum (len + pembro + chemo) as first-line therapy for metastatic non squamous non-small cell lung cancer (NSCLC): Phase III LEAP-006 study
2023 · R.S. Herbst, B.C. Cho, et al. · Immuno-Oncology Technology · 5
PDF
374TiP LAURA: Osimertinib maintenance following definitive chemoradiation therapy (CRT) in patients (pts) with unresectable stage III epidermal growth factor receptor mutation positive (EGFRm) non-small cell lung cancer (NSCLC)
2020 · S. Lu, I. Casarini, et al. · Annals of Oncology · 3
TroFuse-036/GOG-3123/ENGOT-cx22: A 2-part, phase 3, randomized study of sacituzumab tirumotecan (sac-TMT) + pembrolizumab (pembro) ± bevacizumab (bev) vs standard of care (SoC) as first-line maintenance therapy for PD-L1–positive cervical cancer.
2026 · Brian M. Slomovitz, Bradley J. Monk, et al. · Journal of Clinical Oncology · 2
PDF
Patient-reported outcomes from the LAURA study: osimertinib in patients with unresectable stage III EGFR-mutated non-small cell lung cancer after definitive chemoradiotherapy
2026 · Edurne Arriola, Ignacio Casarini, et al. · European Journal of Cancer · 1
508 Biomarker analysis of coformulation of vibostolimab with pembrolizumab (vibo/pembro) with or without docetaxel for metastatic non-small-cell lung cancer (mNSCLC) after chemotherapy and immunotherapy
2025 · Maximilian J Hochmair, Julien Mazieres, et al. · Regular and Young Investigator Award Abstracts · 1
PDF
A Podcast on Osimertinib After CRT in Unresectable Stage III EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC): Current and Future Perspectives
2026 · Thanyanan Reungwetwattana, Kristin A. Higgins, et al. · Targeted Oncology
PDF
Trofuse-036/gog-3123/engot-cx22: a 2-part, Phase 3, Randomized Study of First-line Maintenance Sacituzumab Tirumotecan + Pembrolizumab ± Bevacizumab Vs Standard of Care for Pd-l1–positive Cervical Cancer
2026 · Brian M. Slomovitz, Bradley Monk, et al. · International Journal of Gynecological Cancer
Osimertinib after Definitive Chemoradiotherapy in Unresectable Stage III EGFR-Mutated NSCLC: Subsequent Treatments and Post-progression Outcomes from the Phase III LAURA Study
2026 · Mustafa Özgüroğlu, Myung-Ju Ahn, et al. · Clinical Cancer Research
PDF
48TiP TroFuse-036/GOG-3123/ENGOT-cx22: A 2-part, phase III, randomized study of sacituzumab tirumotecan (sac-TMT) + pembrolizumab (pembro) ± bevacizumab (bev) vs standard of care (SoC) as first-line maintenance therapy for PD-L1–positive cervical cancer
2026 · B.M. Slomovitz, B.J. Monk, et al. · ESMO Open
PDF
149 A Phase 2 Study of Participant-Reported Preference for Pembrolizumab Administered Subcutaneously or Intravenously
2026 · I. Casarini, A. Sumbul, et al. · Journal of the American Pharmacists Association
Participant-Reported Preference for Pembrolizumab Administered Subcutaneously or Intravenously: A Randomized, Open-Label, Phase II Study
2026 · Ignacio A. Casarini, Dariusz M. Kowalski, et al. · JCO Oncology Practice
PDF
INTerpath-013: A phase 2, randomized, double-blind study of intismeran autogene plus pembrolizumab and chemotherapy as first-line treatment for metastatic squamous non–small cell lung cancer.
2026 · Enriqueta Felip, Jhanelle E. Gray, et al. · Journal of Clinical Oncology
PDF
A plain language review of results from the LAURA study: osimertinib after chemoradiotherapy for patients with EGFR-mutated non-small cell lung cancer that cannot be removed by surgery
2026 · Shun Lu, Terufumi Kato, et al. · Future Oncology
PDF
Works count: 33
Citation count: 3,564
H-index: 10
I10-index: 11
Year
Topic
Type